Platycodin D reduces PD‐L1 levels by inhibiting LXR‐β activity and combines with nintedanib to enhance the tumor‐killing effect of T cells

Jin Lei,Xue‐Wei Cao,Peng‐Fei Li,Jian Zhao,Fu‐Jun Wang

DOI: https://doi.org/10.1002/1873-3468.15034

2024-10-22

FEBS Letters

Abstract:We showed that platycodin D (PD), a plant‐derived triterpenoid saponin, downregulated programmed death‐ligand 1 (PD‐L1) protein expression by binding to liver X receptor β (LXR‐β) and inhibiting LXR‐β transcriptional activity, leading to impaired cholesterol efflux and aggregation in lysosomes, and thus affecting PD‐L1 stability. In addition, nintedanib, known to upregulate major histocompatibility complex class I (MHC‐I) expression, and PD coadministration enhanced tumor recognition and killing by T cells and ultimately caused tumor remission. Most tumors are resistant to programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) checkpoint inhibitors, which may be due to impaired antigen presentation resulting from the downregulation of major histocompatibility complex class I (MHC‐I) expression on tumor cells. We observed that platycodin D (PD), polygalacin D, and platycodin D2, which are plant‐derived triterpenoid saponins, significantly reduced PD‐L1 levels. RNA sequencing and the PharmMapper database analysis identified liver X receptor β (LXR‐β) as a potential PD target. Further studies showed that PD reduces PD‐L1 levels by binding to LXR‐β and inhibiting LXR‐β activity. Coadministration of PD and nintedanib, known to upregulate MHC‐I expression, enhanced tumor recognition and killing by T cells. This study provides new insights into PD applications and mechanisms.

cell biology,biochemistry & molecular biology,biophysics